Stoke unveils Dravet data that supported $90M series B

Stoke Therapeutics Inc. (Bedford, Mass.) presented the preclinical data for its Dravet syndrome antisense oligonucleotide (ASO) therapy that CEO Ed Kaye said helped it raise its $90 million series B round in October.

In a mouse model of Dravet syndrome, 99%

Read the full 400 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE